Phase II, multicenter studies of oral LBH589 in patients with chronic phase, accelerated phase or blast phase chronic myeloid leukemia with resistant disease following a treatment with at least bcr-abl-targeting kinase inhibitors
Laufzeit: 01.01.2007 - 31.12.2008